Literature DB >> 33084992

Identification of the Best Prognostic Marker Among Immunonutritional Parameters Using Serum C-Reactive Protein and Albumin in Non-Small Cell Lung Cancer.

Taichi Matsubara1, Shinkichi Takamori1, Naoki Haratake1, Takatoshi Fujishita1, Ryo Toyozawa1, Kensaku Ito1, Mototsugu Shimokawa2, Masafumi Yamaguchi1, Takashi Seto3, Tatsuro Okamoto1.   

Abstract

BACKGROUND: Three immune-nutritional parameters exist for malignant tumors using serum C-reactive protein (CRP) and albumin: the Glasgow prognostic score (GPS), the modified GPS (mGPS), and the CRP-albumin ratio (CAR). However, it remains unclear which of the three parameters is the most predictive of prognosis. Therefore, this study compared the clinical and prognostic significance of these parameters for non-small cell carcinoma (NSCLC).
METHODS: The study retrospectively enrolled 596 NSCLC patients who underwent surgical resection at the authors' institution from January 2010 to December 2015 and investigated the clinicopathologic significance of GPS, mGPS, and CAR. The optimal cutoff value for CAR was determined by a receiver operating curve (ROC).
RESULTS: The median age of the patients was 69 years. Lymph node metastases were identified in 99 patients, and 455 patients had a diagnosis of stage 1 disease. The positivity for GPS was 7.6%, and that of mGPS (score, 1 or 2) was 12.2%. Of the 596 patients, 480 patients (80.5%) were classified in the high CAR group. In univariate survival analyses, all three parameters were associated significantly with postoperative survival. The multivariate analyses showed CAR to be an independent prognostic factor. Additionally, survival analyses of the stage 1 subgroup were performed because CAR was higher for patients with an advanced stage of disease or lymph node metastases. In these subgroup analyses, CAR also was an independent prognostic factor.
CONCLUSION: As the most prognostic index, CAR may be useful among the immunonutritional parameters using CRP and albumin for resected NSCLC.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33084992     DOI: 10.1245/s10434-020-09230-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  20 in total

1.  Prognostic significance of a systemic inflammatory response in patients undergoing multimodality therapy for advanced colorectal cancer.

Authors:  Yasuhiro Inoue; Takashi Iwata; Yoshinaga Okugawa; Aya Kawamoto; Junichiro Hiro; Yuji Toiyama; Koji Tanaka; Keiichi Uchida; Yasuhiko Mohri; Chikao Miki; Masato Kusunoki
Journal:  Oncology       Date:  2012-11-09       Impact factor: 2.935

2.  Identification of subsets of patients with favorable prognosis after recurrence in completely resected non-small cell lung cancer.

Authors:  Makoto Sonobe; Tetsu Yamada; Masaaki Sato; Toshi Menju; Akihiro Aoyama; Toshihiko Sato; Fengshi Chen; Mitsugu Omasa; Toru Bando; Hiroshi Date
Journal:  Ann Surg Oncol       Date:  2014-03-17       Impact factor: 5.344

3.  Ratio of C-reactive protein to albumin is a prognostic factor for operable non-small-cell lung cancer in elderly patients.

Authors:  Takuro Miyazaki; Naoya Yamasaki; Tomoshi Tsuchiya; Keitaro Matsumoto; Masaki Kunizaki; Ryotaro Kamohara; Go Hatachi; Ryoichiro Doi; Tomohiro Obata; Takeshi Nagayasu
Journal:  Surg Today       Date:  2016-11-16       Impact factor: 2.549

4.  A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell Carcinoma.

Authors:  Taichi Matsubara; Kazuki Takada; Koichi Azuma; Shinkichi Takamori; Gouji Toyokawa; Akira Haro; Atsushi Osoegawa; Tetsuzo Tagawa; Akihiko Kawahara; Jun Akiba; Isamu Okamoto; Yoichi Nakanishi; Yoshinao Oda; Tomoaki Hoshino; Yoshihiko Maehara
Journal:  Ann Surg Oncol       Date:  2019-02-27       Impact factor: 5.344

Review 5.  The role of C-reactive protein as a prognostic indicator in advanced cancer.

Authors:  Fade Aziz Mahmoud; Nilo I Rivera
Journal:  Curr Oncol Rep       Date:  2002-05       Impact factor: 5.075

6.  The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.

Authors:  Peter Goldstraw; John Crowley; Kari Chansky; Dorothy J Giroux; Patti A Groome; Ramon Rami-Porta; Pieter E Postmus; Valerie Rusch; Leslie Sobin
Journal:  J Thorac Oncol       Date:  2007-08       Impact factor: 15.609

7.  Predicting postrecurrence survival among completely resected nonsmall-cell lung cancer patients.

Authors:  Brent A Williams; Hiroshi Sugimura; Chiaki Endo; Francis C Nichols; Stephen D Cassivi; Mark S Allen; Peter C Pairolero; Claude Deschamps; Ping Yang
Journal:  Ann Thorac Surg       Date:  2006-03       Impact factor: 4.330

8.  Current outcomes of postrecurrence survival in patients after resection of non-small cell lung cancer.

Authors:  Tetsuya Mizuno; Takaaki Arimura; Hiroaki Kuroda; Noriaki Sakakura; Yasushi Yatabe; Yukinori Sakao
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

9.  Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer.

Authors:  L M Forrest; D C McMillan; C S McArdle; W J Angerson; D J Dunlop
Journal:  Br J Cancer       Date:  2004-05-04       Impact factor: 7.640

10.  The C-reactive protein/albumin ratio predicts long-term outcomes of patients with operable non-small cell lung cancer.

Authors:  Fanrong Zhang; Lisha Ying; Jiaoyue Jin; Kaiyan Chen; Nan Zhang; Junzhou Wu; Yimin Zhang; Dan Su
Journal:  Oncotarget       Date:  2017-01-31
View more
  4 in total

1.  Clinical value and application of a novel nomogram containing inflammatory, nutritional and clinical markers in predicting overall survival of stage II/III gastric cancer patients after radical resection: a bi-centered retrospective study of 2,443 patients.

Authors:  Siyuan Liang; Chuanyi Wei; Liping Tang; Jie Gao; Wenbin Yan; Jiangchun Wu; Ziwen Long; Yanong Wang
Journal:  Am J Transl Res       Date:  2022-07-15       Impact factor: 3.940

2.  The C-reactive protein to albumin ratio is a prognostic factor for stage I non-small cell lung cancer in elderly patients: JACS1303.

Authors:  Takuro Miyazaki; Hisashi Saji; Hiroshige Nakamura; Takeshi Nagayasu; Norihito Okumura; Masanori Tsuchida; Makoto Sonobe; Keiju Aokage; Masayuki Nakao; Tomohiro Haruki; Morihito Okada; Kenji Suzuki; Masayuki Chida; Ichiro Yoshino
Journal:  Surg Today       Date:  2022-02-24       Impact factor: 2.540

3.  Prognostic Utility of Platelet-to-Albumin Ratio among Critically Ill Patients with Colorectal Cancer: A Propensity Score Matching Study.

Authors:  Anshu Li; Zhiyong Wang; Qing Lv; Yan Ling
Journal:  J Oncol       Date:  2022-05-26       Impact factor: 4.501

4.  The advanced lung cancer inflammation index is the optimal inflammatory biomarker of overall survival in patients with lung cancer.

Authors:  Mengmeng Song; Qi Zhang; Chunhua Song; Tong Liu; Xi Zhang; Guotian Ruan; Meng Tang; Hailun Xie; Heyang Zhang; Yizhong Ge; Xiangrui Li; Kangping Zhang; Ming Yang; Qinqin Li; Xiaoyue Liu; Shiqi Lin; Yu Xu; Hongxia Xu; Kunhua Wang; Wei Li; Hanping Shi
Journal:  J Cachexia Sarcopenia Muscle       Date:  2022-07-14       Impact factor: 12.063

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.